A5022604215- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Mechanisms and Therapy
- Gallbladder and Bile Duct Disorders
- Pancreatic and Hepatic Oncology Research
- Pediatric Hepatobiliary Diseases and Treatments
- Liver Disease Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Liver physiology and pathology
- Lung Cancer Treatments and Mutations
- Cancer, Lipids, and Metabolism
- Fibroblast Growth Factor Research
- Ferroptosis and cancer prognosis
- RNA modifications and cancer
- Ocular Oncology and Treatments
- Genetic factors in colorectal cancer
- Chromatin Remodeling and Cancer
- Liver Diseases and Immunity
- Immunotherapy and Immune Responses
- Pancreatic function and diabetes
- Cancer, Hypoxia, and Metabolism
- MicroRNA in disease regulation
- Endoplasmic Reticulum Stress and Disease
Medizinische Hochschule Hannover
2012-2025
Intelligent Transport Systems Niedersachsen
2025
CRUK Lung Cancer Centre of Excellence
2023
University College London
2023
Clinica Universidad de Navarra
2019
Memorial Sloan Kettering Cancer Center
2012-2014
Kettering University
2014
Cold Spring Harbor Laboratory
2013
Klinikum Hanau
2006
Cholangiocarcinoma (CCA) is a rare and heterogeneous biliary cancer, whose incidence related mortality increasing. This study investigates the clinical course of CCA subtypes (intrahepatic [iCCA], perihilar [pCCA], distal [dCCA]) in pan-European cohort.The ENSCCA Registry multicenter observational study. Patients were included if they had histologically proven diagnosis between 2010-2019. Demographic, histomorphological, biochemical, studies performed.Overall, 2,234 patients enrolled...
In recent years, intrahepatic cholangiocarcinoma (iCCA) has evolved as a "role model" for precision oncology in gastrointestinal cancers. However, its rarity, paired with genomic heterogeneity, challenges the development and evolution of targeted therapies. Interrogating large datasets drives better understanding characteristics molecular subgroups rare cancers enables identification patterns that remain unrecognized smaller cohorts.We performed retrospective analysis 6,130 patients...
Significance ROS1 fusion kinases are critical oncogenes in several malignancies, suggesting that inhibitors likely to be effective molecularly targeted therapies these patients. Although phase I/II clinical trials using the ALK/ROS1 inhibitor crizotinib treat fusion-harboring non–small-cell lung cancer patients demonstrate early success, evidence of resistance due acquired G2032R mutation was recently reported. Here, we foretinib is a more potent than vitro and vivo remains against...
Evaluation of the efficacy and safety atezolizumab/bevacizumab in a real-world HCC cohort, including patients with impaired liver function prior systemic therapy.
Genetically engineered mouse models (GEMMs) have greatly expanded our knowledge of pancreatic ductal adenocarcinoma (PDAC) and serve as a critical tool to identify evaluate new treatment strategies. However, the cost time required generate conventional cancer GEMMs limits their use for investigating novel genetic interactions in tumor development maintenance. To address this problem, we developed flexible embryonic stem cell (ESC)-based that facilitate rapid generation genetically defined...
Significance Intrahepatic cholangiocarcinoma (ICC) is a fatal yet understudied primary liver malignancy. To accelerate the functional annotation of cancer genes and therapeutic targets in this disease, we generate highly flexible orthotopic allograft mouse model ICC that can be easily modified vitro to mimic either oncogene expression by retrovirus-mediated gene transfer or tumor-suppressor loss using RNA interference technology. We use demonstrate fused-in-glioblastoma-c-ros-oncogene 1 (...
Background Lenvatinib is approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC). The efficacy of lenvatinib in Caucasian real-world insufficiently defined. purpose this study was to evaluate the a multi-center cohort (ELEVATOR) from Germany and Austria. Methods A retrospective data analysis 205 treated systemic at 14 different sites conducted. Overall survival, progression free overall response rate adverse event rates were assessed analyzed. Results...
Objective Liver fibrosis and cirrhosis resulting from chronic liver injury represent a major healthcare burden worldwide. Growth differentiation factor (GDF) 11 has been recently investigated for its role in rejuvenation of ageing organs, but diseases remained unknown. Here, we the expression function GDF11 fibrosis, common feature most diseases. Design We analysed patients with mouse model hepatic stellate cells (HSCs) as well other cell types. The functional relevance toxin-induced...
Immune-oncology–based regimens have shown efficacy in advanced HCC and been implemented as standard of care first-line therapy. Their efficacy, including high response rates, safety justify their evaluation earlier disease stages. Following negative results for adjuvant sorafenib the global STORM trial 2015, 4 phase 3 trials, featuring different immune checkpoint inhibitor combinations, entered parallel race setting. The IMbrave050 trial, comparing atezolizumab combination with bevacizumab...
The rising incidence of cholangiocarcinoma (CCA) coupled with a low 5‐year survival rate that remains below 10% delineates the urgent need for more effective treatment strategies. Although several recent studies provided detailed information on genetic landscape this fatal malignancy, versatile model systems to functionally dissect immediate clinical relevance identified alterations are still missing. To enhance our understanding CCA pathophysiology and facilitate rapid functional annotation...
Background and Aims: The outcome of patients with HCC who achieved complete response (CR) to immune-checkpoint inhibitor (ICI)–based systemic therapies is unclear. Approach Results: Retrospective study had CR according modified Response Evaluation Criteria in Solid Tumors (CR-mRECIST) ICI-based from 28 centers Asia, Europe, the United States. Of 3933 treated noncurative therapies, 174 (4.4%) CR-mRECIST, 97 (2.5%) RECISTv1.1 (CR-RECISTv1.1) as well. mean age total cohort (male, 85%;...
582 Background: Ablation of neoplastic tissue through radiofrequency ablation (RFA), microwave (MWA), or brachytherapy is a potentially curative option for patients with early stage hepatocellular carcinoma (HCC); however, recurrence rates are high. While updated results from IMbrave050 do not support the use adjuvant therapy following resection local therapy, potential peri-interventional systemic treatment as more effective approach to increase free and long-term survival remains be...